Prostate cancer that progresses despite castrate levels of serum testosterone is defined as castration-resistant prostate cancer (CRPC). Molecular investigations of the disease have established that progression of CRPC remains driven by androgen receptor signalling and that CRPC continues to respond to hormonal manipulation. Recently, new endocrine treatments including an androgen receptor signalling inhibitor and a testosterone synthesis inhibitor have been approved for treatment of CRPC. We review the pivotal phase 3 trials and discuss their implications for future treatment of CRPC.
|Translated title of the contribution||New endocrine treatments prolong survival of patients with castration-resistant prostate cancer.|
|Journal||Ugeskrift for Laeger|
|Number of pages||5|
|Publication status||Published - 30 Sep 2013|